by The global hepatology market size was estimated to be around US$ 13.02 billion in 2022. It is projected to reach US$ 40.22 billion by 2032, indicating a CAGR of 11.94% from 2023 to 2032.
Key Takeaways:
- North America is expected to dominate the hepatology market during the forecast period.
- By treatment type, the antiviral drugs segment is expected to be the dominating segment throughout the forecast period.
- By disease type, the hepatitis segment is expected to be the leading segment of the market. On the other hand, the liver cancer segment will grow at a significant rate during the forecast period.
The market research report on the Hepatology market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Hepatology products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3186
Hepatology Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 14.57 Billion |
| Market Size by 2032 | USD 40.22 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 11.94% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Treatment Type and By Disease Type |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Compounding Pharmacy Market Size to Garner USD 28.19 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Hepatology market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Hepatology market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Hepatology products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Hepatology market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Hepatology market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Hepatology market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Key Players
- Astellas Pharma Inc.
- Merck & Co. Inc.
- Abbott Laboratories
- Bristol- Myers Squibb
- AbbVie Inc.
- Emergent BioSolutions Inc.
- F. Hoffmann- La Roche AG
- Eli Lilly and Company
- Viatris Inc.
- Gilead Sciences, Inc.
Hepatology Market Segmentations
By Treatment Type
- Antiviral Drugs
- Vaccines
- Immunosuppressants
- Targeted Therapy
- Chemotherapy
- Corticosteroids
- Immunoglobulins
By Disease Type
- Hepatitis
- Liver Cancer
- Genetic Disorders
- Autoimmune Diseases
- Non- Alcoholic Fatty Liver Diseases
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Hepatology Market
5.1. COVID-19 Landscape: Hepatology Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Hepatology Market, By Treatment Type
8.1. Hepatology Market, by Treatment Type, 2023-2032
8.1.1. Antiviral Drugs
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Vaccines
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Immunosuppressants
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Targeted Therapy
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Chemotherapy
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Corticosteroids
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Immunoglobulins
8.1.7.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Hepatology Market, By Disease Type
9.1. Hepatology Market, by Disease Type, 2023-2032
9.1.1. Hepatitis
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Liver Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Genetic Disorders
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Autoimmune Diseases
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Non- Alcoholic Fatty Liver Diseases
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Hepatology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Disease Type (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment Type (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Disease Type (2020-2032)
Chapter 11. Company Profiles
11.1. Astellas Pharma Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck & Co. Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbott Laboratories
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Bristol- Myers Squibb
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AbbVie Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Emergent BioSolutions Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. F. Hoffmann- La Roche AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Viatris Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences, Inc.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
